Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics

Travere Therapeutics, Inc. (TVTX): $8.40

0.02 (-0.24%)

POWR Rating

Component Grades








Add TVTX to Watchlist
Sign Up

Industry: Biotech




#156 of 356

in industry

TVTX Price/Volume Stats

Current price $8.40 52-week high $26.55
Prev. close $8.42 52-week low $7.00
Day low $8.25 Volume 97,048
Day high $8.44 Avg. volume 1,426,051
50-day MA $13.47 Dividend yield N/A
200-day MA $17.86 Market Cap 630.09M

TVTX Stock Price Chart Interactive Chart >


  • Value is the dimension where TVTX ranks best; there it ranks ahead of 70.07% of US stocks.
  • The strongest trend for TVTX is in Quality, which has been heading down over the past 177 days.
  • TVTX ranks lowest in Sentiment; there it ranks in the 3rd percentile.

TVTX Stock Summary

  • TVTX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 82.95% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, TRAVERE THERAPEUTICS INC is reporting a growth rate of 37.67%; that's higher than 76.61% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TVTX comes in at -38.42% -- higher than that of just 12.92% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to TRAVERE THERAPEUTICS INC, a group of peers worth examining would be FCEL, KPTI, WATT, CASA, and FKWL.
  • TVTX's SEC filings can be seen here. And to visit TRAVERE THERAPEUTICS INC's official web site, go to

TVTX Valuation Summary

  • In comparison to the median Healthcare stock, TVTX's EV/EBIT ratio is 126.72% lower, now standing at -3.1.
  • TVTX's price/earnings ratio has moved down 0.6 over the prior 131 months.

Below are key valuation metrics over time for TVTX.

Stock Date P/S P/B P/E EV/EBIT
TVTX 2023-09-22 2.6 5.1 -1.9 -3.1
TVTX 2023-09-21 2.5 4.9 -1.9 -3.1
TVTX 2023-09-20 4.3 8.3 -3.1 -4.4
TVTX 2023-09-19 4.4 8.5 -3.2 -4.5
TVTX 2023-09-18 4.4 8.6 -3.3 -4.5
TVTX 2023-09-15 4.5 8.8 -3.3 -4.6

TVTX Growth Metrics

    The 5 year revenue growth rate now stands at 32.8%.
  • Its 3 year net income to common stockholders growth rate is now at -61.4%.
  • The year over year net income to common stockholders growth rate now stands at 9.78%.
Over the past 37 months, TVTX's revenue has gone up $36,680,000.

The table below shows TVTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 212.018 -186.291 -278.482
2022-09-30 213.399 -158.528 -264.232
2022-06-30 228.12 -86.94 -230.215
2022-03-31 228.57 -43.638 -202.195
2021-12-31 227.49 -14.792 -180.091
2021-09-30 221.224 -1.785 -250.14

TVTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TVTX has a Quality Grade of C, ranking ahead of 60.91% of graded US stocks.
  • TVTX's asset turnover comes in at 0.306 -- ranking 150th of 681 Pharmaceutical Products stocks.
  • VTVT, FBRX, and NATR are the stocks whose asset turnover ratios are most correlated with TVTX.

The table below shows TVTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.306 0.969 -0.399
2021-06-30 0.291 0.968 -0.396
2021-03-31 0.289 0.968 -0.412
2020-12-31 0.311 0.969 -0.361
2020-09-30 0.304 0.970 -0.166
2020-06-30 0.303 0.967 -0.194

TVTX Price Target

For more insight on analysts targets of TVTX, see our TVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.71 Average Broker Recommendation 1.25 (Strong Buy)

Travere Therapeutics, Inc. (TVTX) Company Bio

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.

TVTX Latest News Stream

Event/Time News Detail
Loading, please wait...

TVTX Latest Social Stream

Loading social stream, please wait...

View Full TVTX Social Stream

Latest TVTX News From Around the Web

Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023. The Company will al

Yahoo | September 26, 2023

Wayfair upgraded, Deere downgraded: Wall Street's top analyst calls

Today's top research calls for upgrade, downgrade and initiate on stocks, as compiled by The Fly.

Yahoo | September 22, 2023

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year) [p=0.037]. Patients treated with FILSPARI over two years exhibited one of the slowest annual rates of kidney function decline seen in a clinical trial of IgAN patients (-2.7 to -2.9 mL/min/1.73m2 per year)eGFR chronic slope was statistically significant with respect to the confirmatory endpoint for the EU

Yahoo | September 21, 2023

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 8,250 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Pl

Yahoo | September 11, 2023

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

FOSTER CITY, Calif. & SAN DIEGO, September 05, 2023--Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

Yahoo | September 5, 2023

Read More 'TVTX' Stories Here

TVTX Price Returns

1-mo -43.51%
3-mo -45.35%
6-mo -59.87%
1-year -66.96%
3-year -56.17%
5-year N/A
YTD -60.06%
2022 -32.25%
2021 13.89%
2020 91.94%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!